AA
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17 | European journal of cancer |  | 2024 | 12 | 7 | ||
| Neoadjuvant chemo-immunotherapy for early-stage non-small cell lung cancer : a systematic review and meta-analysis | JAMA network open | | 2024 | 17 | 2 | ||
| Unveiling the landscape of uncommon EGFR mutations in NSCLC-A systematic review | Journal of thoracic oncology | | 2024 | 20 | 6 | ||
| Rare synchronous lung cancers in a nonsmoker with epidermal growth factor receptor and mesenchymal-epithelial transition alterations : a case report | Case reports in oncology | | 2024 | 16 | 7 | ||
| The value of high-risk clinicopathologic features for chemotherapy in stage I non-small cell lung cancer : a propensity score-matched study | Journal of thoracic disease | | 2024 | 15 | 5 | ||
| Management of stage III non-small-cell lung cancer : rays of hope | Exploration of targeted anti-tumor therapy | | 2024 | 13 | 2 | ||
| Mobocertinib in patients with EGFR exon 20 insertion-positive non-small cell lung cancer (MOON) : an international real-world safety and efficacy analysis | International journal of molecular sciences | | 2024 | 17 | 2 | ||
| Recommendations for reporting tissue and circulating tumour (ct)DNA next-generation sequencing results in non-small cell lung cancer | British journal of cancer | | 2024 | 15 | 2 | ||
| Oncogenic alterations in advanced NSCLC : a molecular super-highway | Biomarker research | | 2024 | 13 | 7 | ||
| Lung cancer in Switzerland | Journal of thoracic oncology |  | 2024 | 20 | 0 | ||
| Evolving Therapeutic Scenario of Stage III Non-Small-Cell Lung Cancer | Clinical medicine insights. Oncology | | 2023 | 42 | 9 | ||
| Immunotherapy in non-small-cell lung cancer (NSCLC) | Praxis | | 2023 | 22 | 0 | ||
| Safety of extended interval dosing immune checkpoint inhibitors : a multicenter cohort study | Journal of the National Cancer Institute | | 2023 | 19 | 2 | ||
| Bringing immune-checkpoint inhibitors earlier in the management of non-small cell lung cancer | Translational lung cancer research | | 2023 | 45 | 5 | ||
| The evolving role of immune-checkpoint inhibitors in malignant pleural mesothelioma | Journal of clinical medicine | | 2023 | 14 | 3 | ||
| Testing a model of care for patients on immune checkpoint inhibitors based on electronic patient-reported outcomes : protocol for a randomized phase II controlled trial | JMIR research protocols | | 2023 | 18 | 3 | ||
| Detection of genomic mutations in blood and urine free circulating tumour DNA in patients with inoperable and metastatic lung adenocarcinoma harbouring an EGFR mutation in tissue: a UK pilot study | Frontiers in oncology | | 2023 | 71 | 15 | ||
| Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy : a Spinnaker study sub-analysis | Frontiers in oncology | | 2023 | 19 | 3 | ||
| The effects of GCSF primary prophylaxis on survival outcomes and toxicity in patients with advanced non-small cell lung cancer on first-line chemoimmunotherapy : a sub-analysis of the spinnaker study | International journal of molecular sciences | | 2023 | 17 | 2 | ||
| Current approaches to neoadjuvant immunotherapy in resectable non-small cell lung cancer | Current oncology reports | | 2023 | 40 | 7 | ||
| Neoadjuvant immunotherapy : a promising new standard of care | International journal of molecular sciences | | 2023 | 43 | 17 | ||
| Novel targets for immune-checkpoint inhibition in cancer | Cancer treatment reviews | | 2023 | 19 | 4 | ||
| An optimized method to culture human primary lung tumor cell spheroids | Cancers | | 2023 | 41 | 8 | ||
| Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14 | ESMO open | | 2023 | 76 | 35 | ||
| Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors : An INVIDIa-2 study sub-analysis | iScience | | 2023 | 15 | 8 | ||
| RET aberrant cancers and RET inhibitor therapies : Current state-of-the-art and future perspectives | Pharmacology & therapeutics | | 2023 | 14 | 7 | ||
| Quality of life in the adjuvant setting : a meta-analysis of us food and drug administration approved anti-cancer drugs from 2018 to 2022 | Journal of cancer policy | | 2023 | 14 | 3 | ||
| Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non-Small-Cell Lung Cancer : 2-Year Analysis of CodeBreaK 100 | Journal of clinical oncology | | 2023 | 16 | 3 | ||
| UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN) | Journal of thoracic oncology | | 2023 | 28 | 6 | ||
| Pleural mesothelioma in the era of immunotherapy | Clinical medicine insights. Oncology | | 2023 | 18 | 7 | ||
| SARS-CoV-2 m-RNA Vaccine Response in Immunocompromised Patients: A Monocentric Study Comparing Cancer, People Living with HIV, Hematopoietic Stem Cell Transplant Patients and Lung Transplant Recipients | Vaccines | | 2023 | 43 | 15 | ||
| Carrières en oncologie et leadership féminin : les progrès sont-ils au point mort ? | Revue médicale suisse | | 2023 | 30 | 0 | ||
| Development and validation of a DNA damage repair-related gene-based prediction model for the prognosis of lung adenocarcinoma | Journal of thoracic disease | | 2023 | 14 | 2 | ||
| Cellular therapy in NSCLC : between myth and reality | Current oncology reports | | 2023 | 13 | 6 | ||
| Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer : A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium | Journal of clinical oncology | | 2023 | 15 | 3 | ||
| Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study | Lung cancer | | 2022 | 139 | 49 | ||
| Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancer | iScience | | 2022 | 140 | 56 | ||
| The Landscape of Immunotherapy Resistance in NSCLC | Frontiers in oncology | | 2022 | 72 | 44 | ||
| Editorial: Insights in thoracic oncology: 2021/2022 | Frontiers in oncology | | 2022 | 44 | 26 | ||
| A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial | Lung cancer | | 2022 | 167 | 0 | ||
| Real-World Journey of Unresectable Stage III NSCLC Patients: Current Dilemmas for Disease Staging and Treatment | Journal of clinical medicine | | 2022 | 16 | 7 | ||
| Adjuvant treatment for patients with incidentally resected limited disease small cell lung cancer-a retrospective study | Translational lung cancer research | | 2022 | 26 | 6 | ||
| Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial | Cancer | | 2022 | 182 | 260 | ||
| Systemic therapy for pre-treated malignant mesothelioma: A systematic review, meta-analysis and network meta-analysis of randomised controlled trials | European journal of cancer | | 2022 | 24 | 0 | ||
| Efficacy evaluation of surgery combined with chemotherapy for stage IIIA small cell lung cancer patients: a retrospective analysis | Translational lung cancer research | | 2022 | 27 | 3 | ||
| First-Line Treatment for Advanced SCLC: What Is Left Behind and Beyond Chemoimmunotherapy | Frontiers in medicine | | 2022 | 63 | 40 | ||
| International survey on frailty assessment in patients with cancer | The oncologist | | 2022 | 33 | 8 | ||
| Biomarkers for checkpoint inhibitors in NSCLC |  | 2021 | 503 | 0 | |||
| The impact of variant allele frequency in EGFR mutated NSCLCc patients on targeted therapy | Frontiers in Oncology | | 2021 | 277 | 79 | ||
| Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer | Cancer Cell | | 2021 | 196 | 143 | ||
| COVID-19 and lung cancer: risks, mechanisms and treatment interactions | Journal for immunotherapy of cancer | | 2020 | 22 | 4 | ||
| Influence of Concurrent Mutations on Overall Survival in EGFR-mutated Non-small Cell Lung Cancer | Cancer Genomics & Proteomics | | 2020 | 140 | 52 | ||
| Tissue-plasma TMB comparison and plasma TMB monitoring in patients with metastatic non-small cell lung cancer receiving immune checkpoint inhibitors | Frontiers in Oncology | | 2020 | 234 | 175 | ||
| Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation | Gynecologic Oncology Reports | | 2020 | 232 | 137 | ||
| Targeted Therapies in Early Stage NSCLC : Hype or Hope? | International journal of molecular sciences | | 2020 | 29 | 17 | ||
| Prophylactic cranial irradiation in extensive disease small cell lung cancer : an endless debate | Critical reviews in oncology/hematology | | 2019 | 31 | 0 | ||
| Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis | PLOS ONE | | 2019 | 214 | 117 | ||
| Prophylactic Cranial Irradiation in Stage III Non-Small-Cell Lung Cancer: Overall Survival Should Not Necessarily Be the Final End Point | Journal of Clinical Oncology | | 2018 | 410 | 1 | ||
| Learning from the past to design better trials in second-line treatment for mesothelioma patients | Ecancermedicalscience | | 2018 | 286 | 102 |
